On March 6, 2017 Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, reported data presentations relating to its technology platforms to be given at the 2017 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place in Washington, D.C., April 1 through April 5, 2017 (Press release, Aduro Biotech, MAR 6, 2017, View Source [SID1234518003]). Schedule your 30 min Free 1stOncology Demo! Abstract 2645: Development of a first in class APRIL fully blocking antibody BION-1301 for the treatment of multiple myeloma
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Date/Time: Monday, April 3, 1:00 p.m. to 5:00 p.m. ET
Location: Convention Center, Halls A-C
Poster section 26; Board number 4
Abstract 2993: STING signaling in breast tumor microenvironment modulates immune checkpoint blockade efficacy in the neu-N mouse model of breast cancer
Date/Time: Monday, April 3, 3:05 p.m. to 3:20 p.m. ET
Location: Room 152, Level 1, Washington Convention Center
Session: Innate Immune Mechanisms in Cancer Treatment – Oral Presentation
Late-Breaking Research: Immunology
Abstract LB-198:
Combination of PEGylated recombinant hyaluronidase PH20 (PEGPH20) with live-attenuated, double-deleted (LADD) Listeria enhances tumor infiltrating CD8+ T cell response and antitumor efficacy in mice
Date/Time: Tuesday, April 4, 8:00 a.m. to 12:00 p.m. ET
Location: Convention Center, Halls A-C
Poster section 35; Board number 21